Answers are grounded in this paper and cite their sources.
Retrospective cross-sectional study evaluates IHC uptake in breast cancer patients, suggesting need for improved interventions.
e13639 Background: Breast cancer (BCA) is the most common malignancy globally, with highest mortality in Sub-Saharan Africa (SSA). Immunohistochemistry (IHC) is crucial for prognostic and predictive molecular subtyping. Despite the introduction of IHC infrastructure in Nigeria 25 years ago and multi-level interventions, IHC uptake remains low. Methods: This retrospective cross-sectional study assessed IHC uptake among 1,746 newly diagnosed BCA patients at a large tertiary public hospital in Nigeria (2019-2023). IHC rate was calculated as the proportion of patients with recorded molecular receptor subtype data. Treatment plan and mortality outcome were also documented. Results: Only 35.1% (613/1746) of patients obtained IHC workup prior to treatment. Among patients with IHC results, 63.0% were Triple Negative Breast Cancer (TNBC), 26.8% Hormone Receptor Positive, 4.89% Her2 Positive, and 2.44% Triple Positive. Compared to previous reports (21.6%), there's a 14% absolute increase in IHC uptake over a decade. Conclusions: Despite multi-level interventions, IHC uptake remains suboptimal, contributing to high BCA mortality in SSA compared to high income countries. Culturally adapted, patient-facing interventions are needed to improve IHC uptake and mortality outcomes.
No takes yet. Share an insight, caveat, or question.
Subramanian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: